U.S. Auto Components Stock News

NasdaqGS:NDAQ
NasdaqGS:NDAQCapital Markets

Is Nasdaq (NDAQ) Pricing Look Justified After Strong Multi Year Share Gains?

If you are asking whether Nasdaq stock looks reasonably priced or stretched right now, you are in the right place for a clear, valuation focused look at the numbers. The share price closed at US$96.89 recently, with returns of 19.1% over 1 year, 67.0% over 3 years and 118.2% over 5 years. Shorter term moves of a 1.2% decline over 7 days and a 0.2% decline over 30 days show a more muted picture. Recent coverage has focused on Nasdaq's role in capital markets infrastructure and ongoing...
NYSE:CNH
NYSE:CNHMachinery

CNH Industrial’s R4 Robot Extends Automation Push Into Specialty Crop Services

CNH Industrial (NYSE:CNH) has introduced its R4 autonomous robot, aimed at addressing labor shortages in specialty crop farming. The launch focuses on automated solutions for tasks in high value crops where finding and retaining workers can be difficult. This move builds on CNH Industrial's broader push into automation and robotics within agriculture equipment. For you as an investor, the R4 robot sits at the intersection of machinery, software, and farm operations, an area that has been...
NasdaqGS:TLRY
NasdaqGS:TLRYPharmaceuticals

Is Tilray Brands' (TLRY) Italian Medical Push Quietly Redefining Its Global Cannabis Strategy?

Earlier in January 2026, Tilray Medical, a division of Tilray Brands, expanded its European medical cannabis operations by launching Tilray Medical Italia, rebranding the former FL Group and broadening an Italian Ministry of Health–authorized product portfolio in partnership with Molteni Farmaceutici. This move not only deepens Tilray’s presence in one of Europe’s most tightly regulated medical cannabis markets, it also advances its goal of building a unified global medical cannabis platform...
NasdaqGM:WVE
NasdaqGM:WVEPharmaceuticals

How Investors May Respond To Wave Life Sciences (WVE) Expanding PRISM RNA Platform Via Big-Pharma Partnerships

In recent months, Wave Life Sciences has drawn increased attention for its PRISM RNA medicines platform and its work with partners including GlaxoSmithKline, Takeda Pharmaceutical, and Asuragen to advance novel therapies. An interesting aspect of this story is how these collaborations may help Wave Life Sciences expand its research reach while sharing development and commercialization expertise with larger pharmaceutical companies. Next, we will examine how the PRISM RNA medicines platform...
NYSE:MOH
NYSE:MOHHealthcare

A Look At Molina Healthcare (MOH) Valuation After Medicare Advantage Payment Shock And Guidance Pressure

The Molina Healthcare (MOH) share move was driven by a policy shock after the Centers for Medicare & Medicaid Services proposed just a 0.09% net payment increase for 2027 Medicare Advantage plans. See our latest analysis for Molina Healthcare. At a share price of US$179.59, Molina’s recent 1 day share price return of a 2.89% decline and 7 day share price return of an 11.05% decline sit against a 90 day share price return of 17.33%. The 1 year total shareholder return of a 42.14% decline...
NYSE:EME
NYSE:EMEConstruction

How Investors May Respond To EMCOR Group (EME) Upgraded 2025 Outlook And Acquisition-Fueled Expansion

EMCOR Group has recently attracted positive attention after highlighting strong financial strength, profitability, and growth metrics, supported by rising demand across key electrical and mechanical construction end markets and several 2025 acquisitions, including Miller Electric. The company’s raised 2025 revenue, operating margin, and EPS outlook, alongside high-quality analyst endorsement, underscores management’s confidence and its perceived competitive position within facilities...
NasdaqGS:IMCR
NasdaqGS:IMCRBiotechs

Immunocore Reshapes R&D Leadership As Shares Trade Below Analyst Targets

Immunocore Holdings (NasdaqGS:IMCR) announced an overhaul of its R&D leadership following the planned departure of EVP of Research & Development, Dr. David Berman. Instead of appointing a direct successor, the company is expanding the responsibilities of internal leaders Dr. Mohammed Dar and Mark Moyer. The leadership changes are expected to reshape how Immunocore manages clinical development and regulatory activities. Immunocore Holdings enters this leadership transition with its shares...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

CorMedix Analyst Day Highlights Infection Prevention Plans For REZZAYO And DefenCath

CorMedix (NasdaqGM:CRMD) is hosting an analyst day focused on its late stage clinical programs. The event will feature updates on REZZAYO for fungal infection prophylaxis and DefenCath for catheter related bloodstream infection prevention. Management is expected to outline current program status and broader business direction for these key assets. For investors watching CorMedix, the focus is on how these late stage assets fit into the broader infection prevention space. REZZAYO and...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Rezdiffra Growth Expectations

Madrigal Pharmaceuticals (MDGL) has recently drawn attention after a mixed pattern in its share performance, with a negative month return but a positive move over the past 3 months and a strong one year total return. See our latest analysis for Madrigal Pharmaceuticals. Recent trading has been choppy, with a 30 day share price return of a 16% decline and a year to date share price return of an 18% decline, yet the 1 year total shareholder return of 46% suggests longer term momentum has still...
NasdaqGM:TVTX
NasdaqGM:TVTXBiotechs

Is Travere Therapeutics (TVTX) Offering Value After Recent Share Price Swings?

If you are wondering whether Travere Therapeutics at around US$31.09 is offering fair value or an opportunity, you are not alone. This article is built to help you size that up clearly. The stock has had a mixed run, with a 5.6% gain over the last 7 days but an 18.6% decline over 30 days, while still sitting on a 52.0% return over 1 year and 43.1% over 3 years, compared with a 2.1% decline over 5 years. Recent coverage of Travere Therapeutics has focused on its position in the...
NYSE:DUK
NYSE:DUKElectric Utilities

Duke Energy Winter Storm Response And Grid Resilience Story For Investors

Duke Energy prepared for severe winter weather in the Carolinas and Florida with grid hardening work and customer safety outreach. The company activated response plans as storms moved through, leading to widespread outages across parts of its service territory. Crews were deployed for large scale restoration efforts, supported by advanced self healing grid technologies aimed at shortening outages. Duke Energy, trading as NYSE:DUK, sits at the center of a major power reliability story as...
NasdaqCM:WULF
NasdaqCM:WULFSoftware

TeraWulf (WULF) Valuation Check As AI And HPC Financing And Contracts Gain Momentum

TeraWulf (WULF) is drawing fresh investor attention after securing large financing for high performance computing and AI facilities, backed by long term HPC contracts and support from partners such as Google and Fluidstack. See our latest analysis for TeraWulf. The latest funding news comes after a sharp pullback, with a 1 day share price return of an 8.05% decline and a 7 day share price return of a 5.31% decline. However, the 30 day share price return of 16.36% and the very large 3 year...
NYSE:GD
NYSE:GDAerospace & Defense

Is It Too Late To Consider General Dynamics (GD) After Its Strong Multi Year Run?

If you are wondering whether General Dynamics shares still offer value after a strong run, this article walks through what the current price might be implying about the business. The stock last closed at US$351.09, with a 1 year return of 39.3% and a 5 year return of 146.4%, while the past week shows a 3.4% decline and the past month a 4.3% gain. These figures can change how investors think about both opportunity and risk. Recent news coverage has focused on General Dynamics as a major US...
NYSE:ANF
NYSE:ANFSpecialty Retail

A Look At Abercrombie & Fitch (ANF) Valuation After Its New NFL Super Bowl Fashion Partnership

Abercrombie & Fitch (ANF) is back in focus after being named the NFL's Official Fashion Partner for the upcoming Super Bowl, tying its stock story to high visibility events across sports and fashion. See our latest analysis for Abercrombie & Fitch. The Super Bowl tie up comes at a time when Abercrombie & Fitch’s share price of $97.63 sits below recent highs. A 90 day share price return of 34.57% contrasts with a 22.44% decline over 30 days and a three year total shareholder return of 224.68%,...
NYSE:AEM
NYSE:AEMMetals and Mining

Agnico Eagle Refines Portfolio With Barsele Sale And Royalty Exposure

Agnico Eagle Mines (NYSE:AEM) has agreed to sell its remaining 55% stake in Gunnarn Mining AB, including the Barsele project, to Goldsky Resources. The company will retain a royalty interest on the project, aligning with its portfolio optimization approach. The transaction structure includes cash, equity in Goldsky Resources, and ongoing royalty exposure. Agnico Eagle Mines is a major gold producer, so any portfolio reshaping around projects like Barsele can matter for how its asset base...
NYSE:LUV
NYSE:LUVAirlines

Is It Too Late To Consider Southwest Airlines (LUV) After Its Strong Share Price Run?

If you are wondering whether Southwest Airlines is still fairly priced after its recent run, you are not alone. This article focuses squarely on what the current share price might be implying. The stock recently closed at US$47.52, with returns of 13.3% over 7 days, 15.0% over 30 days, 15.1% year to date, 58.1% over 1 year and 39.8% over 3 years, while the 5 year return stands at 2.0%. Recent headlines around Southwest Airlines have focused on its operational recovery and route capacity...
NYSE:MPC
NYSE:MPCOil and Gas

Assessing Marathon Petroleum (MPC) Valuation After New US$1.00 Dividend Declaration

Dividend declaration and why it matters now Marathon Petroleum (MPC) has just declared a US$1.00 per share common stock dividend, payable on March 10, 2026 to shareholders of record at the close of business on February 18, 2026. See our latest analysis for Marathon Petroleum. At a share price of US$176.19, Marathon Petroleum has seen an 8.34% 1 month share price return and a 6.69% year to date share price return, while its 1 year total shareholder return of 23.60% and very large 5 year total...
NasdaqGM:USAR
NasdaqGM:USARMetals and Mining

USA Rare Earth Faces Dilution Question After Landmark U.S. Backing

USA Rare Earth (NasdaqGM:USAR) has secured a $1.3b U.S. federal loan, a $277m direct federal equity investment, and a $1.5b private placement. The funding package makes the U.S. government one of USAR's largest shareholders and supports a domestic mine to magnet supply chain. The transaction introduces milestone based funding and no price supports, setting different terms compared with some peers in critical minerals. For investors watching critical minerals, USA Rare Earth now sits at the...
NYSE:SCCO
NYSE:SCCOMetals and Mining

How Investors Are Reacting To Southern Copper (SCCO) Record Profits Amid Lower Output And Market Deficit

Southern Copper Corporation recently reported fourth-quarter 2025 sales of US$3,869.8 million and net income of US$1,307.9 million, capping a year in which full-year sales reached US$13.42 billion and net income climbed to US$4.33 billion. Alongside these record results, management flagged a copper market deficit and lower near-term production due to declining ore grades in Peru, while still committing to substantial growth projects like the Tía María development. Next, we’ll examine how...
NasdaqGS:ZBRA
NasdaqGS:ZBRAElectronic

Did Zebra’s AI Inspection Tie-Up with Sentinel Just Shift Zebra Technologies' (ZBRA) Automation Narrative?

In late January 2026, Zebra Technologies highlighted that Sentinel’s automotive customers are using its Poka Yoke inspection solution, combining Zebra’s AltiZ Series High-Fidelity 3D Profile Sensor with Sentinel’s Vision Core AI software to cut defect rates and speed up machine commissioning. This collaboration underscores how Zebra’s vision and RFID technologies are being applied across both factory floors and NFL fields to deliver real-time, data-rich insights. We’ll now examine how this...
NYSE:GENI
NYSE:GENIHospitality

Reassessing Genius Sports (GENI) After Recent Share Price Weakness And DCF Upside Potential

If you are wondering whether Genius Sports is offering fair value at its current price, you are not alone, as the stock has been attracting attention from investors who want to know what they are really paying for its growth story. The shares last closed at US$8.70, with returns of a 10% decline over 7 days, a 21.1% decline over 30 days, a 19.3% decline year to date and a 1.5% decline over 1 year, while the 3 year return sits at 59.3% and the 5 year return at a 58.1% decline. Recent news...
NasdaqGM:CRSP
NasdaqGM:CRSPBiotechs

ARK’s Bigger CRISPR Therapeutics Stake Underscores Gene Editing Pipeline Story

ARK Investment Management has significantly expanded its position in CRISPR Therapeutics (NasdaqGM:CRSP), purchasing a large block of shares. The move highlights ARK's confidence in CRISPR Therapeutics' role in gene editing and its clinical pipeline. The news coincides with continued work on gene editing therapies targeting beta thalassemia, sickle cell disease, cardiovascular conditions, and type 1 diabetes. CRISPR Therapeutics' share price recently stood at $49.96, with the stock showing...
NYSE:SE
NYSE:SEMultiline Retail

Sea Balances Rapid Profitability With Renewed Growth Spending And Mixed Sentiment

Sea Limited (NYSE:SE) recently reported quarterly results with strong growth across e-commerce, digital financial services, and digital entertainment. The company returned to profitability and outpaced earlier expectations for both revenue and earnings. Management highlighted plans to prioritize long-term growth investments in logistics, fulfillment, and membership programs instead of focusing on near term margin expansion. Sea also reported growing contributions from higher margin ad...
NasdaqCM:CLSK
NasdaqCM:CLSKSoftware

CleanSpark (CLSK) Valuation Check After Recent Share Price Pullback And Mixed Long Term Returns

CleanSpark (CLSK) has drawn fresh attention after recent trading moves left the bitcoin miner with a year to date return close to 3%, despite a decline of about 33% over the past 3 months. See our latest analysis for CleanSpark. The recent pullback, including a 1-day share price return of a 5.96% decline and a 7-day share price return of a 13.64% decline from the latest close at $11.84, comes after a 30-day share price return of 17.00% and a 1-year total shareholder return of 13.41%. Recent...